Two pediatric cases of reticular corneal epithelial edema associated with netarsudil

Aparicio, Maria A Guzman; Liebman, Daniel; Chodosh, James; Freitag, Suzanne K.; Kazlas, Melanie; Derek, D.; Marando, Catherine M.; Mukai, Sonoyo; Wu, Annie M.; Chen, Teresa C.

doi:10.1016/j.ajoc.2022.101638

Cited by 6 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients that develop corneal oedema are likely to have risk factors such as reduced endothelial cell count, epithelial defects, or a history of penetrating keratoplasty [46,71]. Netarsudilassociated cornea oedema has been reported to occur in children [73]; one case of corneal flattening was also reported in a child [74].…”

Section: Safety Profile Of Netarsudilmentioning

confidence: 99%

ROCK Inhibitors in Corneal Diseases and Glaucoma—A Comprehensive Review of These Emerging Drugs

Pagano,

Lee,

Posarelli

et al. 2023

JCM

View full text Add to dashboard Cite

Rho kinase (ROCK) inhibitors have gained significant attention as emerging novel treatment options in the field of ophthalmology in recent years. The evidence supporting their efficacy in glaucoma and corneal pathology includes both in vitro and clinical studies. Among the available options, ripasudil and netarsudil have emerged as the leading ROCK inhibitors, and some countries have approved these therapeutic options as treatments for glaucoma. Various dosing regimens have been studied, including monotherapy and combination therapy, especially for patients with secondary glaucoma who are already on multiple medications. Another rising application of ROCK inhibitors includes their use as an adjunct in surgical procedures such as Descemetorhexis Without Endothelial Keratoplasty (DWEK), Descemet Stripping Only (DSO) to accelerate visual recovery, glaucoma surgeries to reduce scarring process and allow better intraocular pressure (IOP) control, or after complicated anterior segment surgery to treat corneal oedema. This article provides a comprehensive overview of the existing literature in the field, offering recommendations for prescribing ROCK inhibitors and also discussing patient selection, drug efficacy, and possible adverse effects.

show abstract

Section: Safety Profile Of Netarsudilmentioning

confidence: 99%

ROCK Inhibitors in Corneal Diseases and Glaucoma—A Comprehensive Review of These Emerging Drugs

Pagano,

Lee,

Posarelli

et al. 2023

JCM

View full text Add to dashboard Cite

show abstract

“…More reports feature in recent literature on the topical use of netarsudil 0.02% (Rho-Kinase inhibitor and norepinephrine transport inhibitor), causing macrocellular reticular pattern of epithelial edema in eyes with pre-existing stromal edema and raised intraocular pressure. [ 2 3 4 5 6 7 8 ] This unique pattern of edema has been observed in the clinical setting of pre-existing endothelial cell dysfunction when netarsudil is used. Rho-kinase (ROCK) inhibitors regulate and increase the permeability of tight junctions, thereby permitting fluid movement from the corneal stroma to the epithelium.…”

mentioning

confidence: 93%

Letter to Editor on “Nair AV, Rosette D, Rajaraman R. Netarsudil-associated reticular epithelial edema in a corneal ulcer. Indian J Ophthalmol Case Rep 2022; 2:649-51”

Vanathi

Beniwal

2023

Indian Journal of Ophthalmology

View full text Add to dashboard Cite

Netarsudil

2022

Reactions Weekly

View full text Add to dashboard Cite

Two pediatric cases of reticular corneal epithelial edema associated with netarsudil

Cited by 6 publications

References 12 publications

ROCK Inhibitors in Corneal Diseases and Glaucoma—A Comprehensive Review of These Emerging Drugs

ROCK Inhibitors in Corneal Diseases and Glaucoma—A Comprehensive Review of These Emerging Drugs

Letter to Editor on “Nair AV, Rosette D, Rajaraman R. Netarsudil-associated reticular epithelial edema in a corneal ulcer. Indian J Ophthalmol Case Rep 2022; 2:649-51”

Netarsudil

Contact Info

Product

Resources

About